Recurrent autoimmune encephalitis related to immune checkpoint inhibitors
Corresponding Author
Merve Hazal Ser
Department of Neurology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey
Correspondence: Merve Hazal Ser Department of Neurology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey <[email protected]> <[email protected]>Search for more papers by this authorNilay Şengül Samanci
Department of Oncology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey
Search for more papers by this authorNaziye AK
Department of Oncology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey
Search for more papers by this authorAdnan Aydiner
Department of Oncology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey
Search for more papers by this authorÇiğdem Özkara
Department of Neurology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey
Search for more papers by this authorCorresponding Author
Merve Hazal Ser
Department of Neurology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey
Correspondence: Merve Hazal Ser Department of Neurology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey <[email protected]> <[email protected]>Search for more papers by this authorNilay Şengül Samanci
Department of Oncology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey
Search for more papers by this authorNaziye AK
Department of Oncology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey
Search for more papers by this authorAdnan Aydiner
Department of Oncology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey
Search for more papers by this authorÇiğdem Özkara
Department of Neurology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey
Search for more papers by this author
Supporting Information
| Filename | Description |
|---|---|
| epd212551-sup-9001.pptxapplication/pptx, 209.4 KB | slides |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 2018; 115: 71–4.
- 2Özdirik B, Jost-Brinkmann F, Savic LJ, Mohr R, Tacke F, Ploner CJ, et al. Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: case report and literature review. Medicine (Baltimore) 2021; 100 (24): e26377.
- 3Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15(4): 391–404.
- 4Dubey D, Kothapalli N, McKeon A, Flanagan EP, Lennon VA, Klein CJ, et al. Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction. J Neuroimmunol 2018; 323: 62–72.
- 5Dubey D, Singh J, Britton JW, Pittock SJ, Flanagan EP, Lennon VA, et al. Predictive models in the diagnosis and treatment of autoimmune epilepsy. Epilepsia 2017; 58: 1181–9.
- 6Du Four S, Hong A, Chan M, Charakidis M, Duerinck J, Wilgenhof S, et al. Symptomatic histologically proven necrosis of brain following stereotactic radiation and ipilimumab in six lesions in four melanoma patients. Case Rep Oncol Med 2014; 417913.
- 7Williams TJ, Benavides DR, Patrice KA, Dalmau JO, de Ávila AL, Le DT, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 2016; 73: 928–33.
- 8Bross SP, Mongelluzzo GJ, Conger AR, Patel MA, Vadakara J, Grant M, et al. Case report of immuno-oncotherapy (IO) provoked encephalitis mimicking brain metastasis in a patient with history of traumatic brain injury. World Neurosurg 2020; 139: 483–7.
- 9Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 2018; 36(17): 1714–68.
- 10Stuby J, Herren T, Schwegler Naumburger G, Papet C, Rudiger A. Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature. Swiss Med Wkly 2020; 150: w20377.
Citing Literature
